Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Yellow Fever

Yellow Fever

Yellow fever is a viral hemorrhagic disease caused by the yellow fever virus (YFV), a member of the Flaviviridae family. It is transmitted primarily by Aedes and Haemagogus mosquitoes in tropical and subtropical regions of Africa and South America. After transmission through a mosquito bite, the virus initially replicates in skin-resident immune cells such as dendritic cells and macrophages. These cells then migrate to the lymph nodes, where viral replication increases, eventually leading to...

Vaccinations

Vaccinations

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Same author

Enhancing, controlling, and sterilizing dengue immunity and the development of broadly protective responses.

medRxiv : the preprint server for health sciences·2026

Same author

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine.

Nature medicine·2026

Same author

Sub-neutralizing concentrations of Zika virus IgM monoclonal antibodies reduce IgG-mediated antibody-dependent enhancement of infectivity.

bioRxiv : the preprint server for biology·2026

Same author

Corrigendum to 'Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome' Journal of Investigative Dermatology Volume 145, Issue 8, August 2025, Pages 2021-2033.e3.

The Journal of investigative dermatology·2026

Same author

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model.

The New England journal of medicine·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

Dengue vaccine candidates in development.

Anna P Durbin¹, Stephen S Whitehead

¹Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. adurbin@jhsph.edu

Current Topics in Microbiology and Immunology

|October 6, 2009

Summary

A successful dengue vaccine must protect against all four serotypes due to risks from prior infections. Live attenuated vaccines are most advanced, with several candidates in clinical trials.

Area of Science:

Virology and Immunology
Vaccinology
Infectious Diseases

Background:

Dengue virus (DENV) has four serotypes, each capable of causing a wide range of illness severity.
Pre-existing antibodies from a previous infection with one DENV serotype can increase the risk of severe dengue upon subsequent infection with a different serotype.
This phenomenon, known as antibody-dependent enhancement, highlights the complexity of dengue pathogenesis and vaccine development.

Purpose of the Study:

To review the current landscape of dengue vaccine development, emphasizing the need for tetravalent vaccines.
To discuss vaccine candidates that offer protection against all four DENV serotypes.
To evaluate the progress of various vaccine platforms in preclinical and clinical stages.

Main Methods:

More Related Videos

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Related Experiment Videos

Last Updated: Jun 19, 2026

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Multiplexed Isothermal Amplification Based Diagnostic Platform to Detect Zika, Chikungunya, and Dengue 1

Published on: March 13, 2018

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Review of existing epidemiological studies on dengue serotype interactions and disease severity.
Analysis of ongoing research and development for dengue vaccine candidates.
Discussion of vaccine platforms including live attenuated, inactivated, recombinant subunit, DNA, and viral-vector vaccines.

Main Results:

Live attenuated tetravalent dengue vaccine candidates are the most advanced, with two currently in Phase 2 clinical trials.
Multiple other vaccine strategies are under investigation, indicating diverse approaches to dengue prevention.
The discussion encompasses vaccine candidates that have undergone preclinical animal model testing or human clinical trials.

Conclusions:

A universal dengue vaccine must provide robust protection against all four DENV serotypes to be effective and safe.
Live attenuated vaccines represent a promising strategy, with ongoing trials providing critical data on efficacy and safety.
Continued development across various platforms is essential to address the global burden of dengue.